Speaker: Evangelos Terpos

0:02:39

Antibody response to COVID-19 vaccine in patients with multiple myeloma and WM

0:01:40

Open questions in the use of imaging techniques for assessing response in multiple myeloma

0:03:11

Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM

0:02:38

Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing

0:03:22

The role of imaging techniques in defining response in multiple myeloma

0:02:25

HRQoL outcomes in the APOLLO trial

0:01:57

Promising new combinations in the treatment of myeloma

0:51:52

37_Advances of the management of Multiple Myeloma_11th March, 2025

0:02:02

Ocular AEs observed in patients treated with belantamab mafodotin, lenalidomide & dexamethasone

0:03:47

REBUILD: effect of daratumumab on bone metabolism in R/R myeloma

0:01:14

BelaRd: belantamab mafodotin with lenalidomide and dexamethasone in patients with NDMM

0:03:42

Surrogate markers in patients with R/R myeloma receiving belantamab mafodotin

0:04:59

Daratumumab reduces carfilzomib-related cardiac toxicities in R/R myeloma

0:02:31

Sustained MRD negativity for three years can guide discontinuation of LEN maintenance in myeloma

0:04:38

First results of a prospective trial of the BNT162B2 mRNA COVID-19 vaccine

0:02:18

DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients

0:52:52

Post COMy-ASCO-EHA round table - Antibody-drug conjugates in RRMM

0:06:39

Anti-SARS-CoV-2 antibodies titers in convalescent plasma donors

0:04:26

Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?

1:28:17

Lymphoma & Myeloma Management During COVID-19 pandemic Webinar

0:01:34

iNNOVATE study update: long-term PFS in WM

0:06:10

History of the IWWM - Part-1

0:08:13

Proteasome inhibitors: key drugs in multiple myeloma

0:01:42

First-in-human trial of an anti-BCMA ADC for R/R myeloma